Phosphate burden in chronic kidney disease (CKD) leads to elevated serum fibroblast factor-23 (FGF-23) levels, secondary hyperparathyroidism and chronic kidney disease-mineral bone disorder (CKD-MBD). However dissociated hyperphosphatemia and low serum FGF-23 concentrations have been observed in experimentally parathyoridectomized rats. The relationships between serum mineral, hormone, and bone metabolism may be altered in the presence of CKD. The aim of our study was to investigate whether a consistent relationship existed between serum FGF-23 levels, specific serum biochemical markers, and histomorphometric parameters of bone metabolism in a parathyroidectomized CKD animal model.
Sprague Dawley rats were divided into 3 groups: parathyroidectomy (PTX) and CKD (PTX+CKD, 9 rats), CKD without PTX (CKD, 9 rats), and neither PTX nor CKD (sham-operated control, 8 rats); CKD was induced by partial nephrectomy. At 8 weeks after partial nephrectomy, serum biomarkers were measured. Bone histomorphometries of the distal femoral metaphyseal bone were analyzed. The mean serum FGF-23 levels and mean bone formation rate were the highest in the CKD group and the lowest in the PTX+CKD group. Bone volume parameters increased significantly in the PTX+CKD group. Pearson’s correlation revealed that serum FGF-23 levels associated with those of intact parathyroid hormone, phosphate, collagen type I C-telopeptide, and calcium. Univariate linear regression showed that serum FGF-23 values correlated with bone formation rate, bone volume, and osteoid parameters. Stepwise multivariate regression analysis revealed that circulating FGF-23 values were independently associated with bone volume and thickness (β = -0.737; p < 0.001 and β = -0.526; p = 0.006, respectively). Serum parathyroid hormone levels independently correlated with bone formation rate (β = 0.714; p < 0.001) while collagen type I C-telopeptide levels correlated with osteoid parameter.
Citation: Liao H-W, Hung P-H, Hsiao C-Y, Liou H-H, Lin H-S, Huang T-H, et al. (2015) Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy. PLoS ONE 10(7): e0133278. https://doi.org/10.1371/journal.pone.0133278
Editor: Ching-Po Lin, National Yang-Ming University, TAIWAN
Received: January 15, 2015; Accepted: June 23, 2015; Published: July 17, 2015
Copyright: © 2015 Liao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This study was supported by National Cheng Kung University Hospital (NCKUH-10408012) and National Cheng Kung University.
Competing interests: The authors have declared that no competing interests exist.
In chronic kidney disease, CKD-mineral and bone disorder (CKD-MBD) is a disturbance in mineral metabolism and bone remodeling. Subsequently, vascular calcification may develop. CKD-MBD affects many patients who have CKD and increases their morbidity and mortality [1–4]. The onset of CKD-MBD is considered to be caused by an abnormality in mineral metabolism when renal function declines. Subsequently, hormone dysregulation, osteodystrophy, and cardiovascular complication appear.
Fibroblast growth factor23 (FGF-23) is a regulator of phosphate metabolism and is elevated in patients with CKD . The hormone FGF-23 is derived mainly from osteocytes in bone [6,7] and acts on proximal renal tubules to maintain serum phosphate homeostasis [8,9] by excreting excess phosphate through the kidney [10,11]. In CKD, phosphate retention occurs as functional renal mass diminishes; this stimulates FGF-23 synthesis to increase renal excretion of excess phosphate . Although disrupted phosphate homeostasis in patients with CKD also induces secondary hyperparathyroidism, the elevation of serum FGF-23 occurs earlier than that of serum PTH levels [13,14].
Since FGF-23 regulates serum mineral homeostasis and derives from bone, FGF-23 has effect on bone metabolism. It has been suggested that FGF-23 is directly associated with bone metabolism. Treatment with resorption inhibitors or anabolic agents could modulate bone formation rate and simultaneously influence circulating FGF-23 concentrations . In patients with CKD, hyperphosphatemia and secondary hyperparathyroidism lead to a high turnover of bone disease [16,17]. Since serum FGF-23 concentrations concurrently rise in these patients, a high turnover bone disease may accompany high levels of FGF-23 . Furthermore, an independent negative association between FGF-23 and bone mineral density at the total hip and femoral neck has also been observed in CKD stage 4 patients .
Nevertheless, changes in serum FGF-23 levels are not always associated with changes in serum phosphate concentration, according to results from animal studies . In rodents subjected to parathyroidectomy (PTX), a dissociated change in serum phosphate and FGF-23 levels was observed. This dissociation makes the principle that chronic phosphate burden in CKD resulting in increased serum PTH and FGF-23 levels and leading to renal osteodystrophy may not be consistent when present in PTX animals accompanied by renal failure. As a result, the relationship between hormone levels and bone metabolism may be altered. We questioned whether serum FGF-23 levels correlated with changes in parameters of bone metabolism when a model included underwent PTX and renal failure animals.
Therefore, we designed an experimental CKD model combined with PTX in which serum phosphate and FGF-23 levels were dissociated. We investigated the relationship between FGF-23, biochemical markers, and bone histomorphometric parameters in this model with the aim of providing more information concerning hormone and bone metabolism in CKD.
Materials and Methods
Six-week-old male Sprague Dawley rats were housed under controlled conditions (room temperature, 22°C ± 1°C; alternating 12-h light and dark periods). All animals were given rat chow (Purina Rodent Chow 5001, Labdiet, Richmond, IN) containing 0.95% calcium and 1.07% phosphate (weight/weight dry food) and tap water ad libitum throughout the study. The National Cheng Kung University Animal Ethics Committee approved all of the experimental procedures (Permit Number: 100269). The care and handling of the animals were in accordance with the National Institute of Health guidelines for ethical treatment of animals. All surgery was performed under anesthesia, and all efforts were made to minimize suffering.
After the rats were acclimatized to the laboratory environment for 1 week, they were randomly divided into 3 groups: PTX and CKD (PTX+CKD, 9 rats), CKD without PTX (CKD, 9 rats), and neither PTX nor CKD (sham-operated control, 8 rats). The PTX+CKD group underwent PTX caused by electrocautery under a dissecting microscope [21,22] after anesthesia. Anesthesia was induced with 5% isoflurane mixed with 70% N2O and 30% O2 in an induction chamber and regulated as necessary. Surgical-depth anesthesia was maintained with 1.5% isoflurane. The parathyroid glands of the other rats (CKD and sham-operated control) were exposed, but electrocautery was not performed. In all 9 PTX+CKD rats, blood samples withdrawn 3 days after PTX showed serum calcium levels < 6.0 mg/dL that were confirmed successful PTX .
For the PTX+CKD rats (1 week after PTX) and CKD rat models, CKD was induced by a partial nephrectomy performed as a 2-step procedure with general anesthesia as described previously [21–23]; in sham-operated control rats, the kidneys were exposed but no nephrectomy was performed. At 8 weeks after induction of CKD, blood samples were obtained by intracardiac puncture (all 26 rats) after general anesthesia, spot urine samples were collected (feasible only in 19 rats), and the rats were euthanized. Serum was separated immediately by centrifugation (1500×g for 15 min) and stored at −75°C for future assays.
Blood and Urine Assays
Serum was analyzed for blood urea nitrogen (BUN), creatinine (Cr), phosphate, calcium, and alkaline phosphatase (ALP) levels with an automatic chemistry analyzer. Enzyme-linked immunosorbent assay kits were used to measure levels of serum intact parathyroid hormone (PTH,ALPCO, Salem, NH), FGF-23 (Kainos Laboratories, Tokyo, Japan), osteocalcin (Biomedical Technologies, Inc., Stoughton, MA), 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) (MyBioSource, Inc., San Diego, USA) and collagen type I C-telopeptide (CTX) (MyBioSource, Inc., San Diego, USA) levels. Urine chemistry values were measured with an automatic chemistry analyzer. Urinary fractional excretion of phosphate was calculated as (urine phosphate × serum creatinine) × [100/(serum phosphate × urine creatinine)]. The same equation was applied to calculate urinary fractional excretion of calcium.
The rats were injected intraperitoneally with calcein (20 mg/kg) (Sigma-Aldrich, St Louis, MO) 10 days and 3 days before being euthanized. After death, the distal femurs were excised, placed in 70% ethanol, and dehydrated. Specimens were embedded in methyl methacrylate according to the manufacturer (Fluka, 64200, Sigma-Aldrich, St Louis, MO) and not decalcified. Longitudinal sections (thickness, 5μm) were made in the sagittal plane with a motorized microtome (Microm HM 355S, Microm International GmbH, Walldorf, Germany) and stained with Masson trichrome.
Quantitative study of the distal femoral metaphysis was performed according to histomorphometric procedures as described previously [24–26] and evaluated using image analysis software (Image Pro Plus 6.1 for Windows; Media Cybernetics, Silver Spring, MD). The bone turnover, mineralization, and volume (TMV) classification, suggested by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, was used to assess renal osteodystrophy . Volume histomorphometric parameters were measured including bone volume ratio (BV/TV) (%), trabecular thickness (μm), trabecular separation (space between trabeculae, μm), and trabecular number (1/mm). The femoral sections were photographed under a fluorescent light microscope (×200) using a digital camera (COOLPIX 4500; Nikon, Tokyo, Japan). Osteoid parameters were measured as osteoid volume ratio (1) (OV/BV) = osteoid volume/bone volume; (2) osteoid surface ratio (OS/BS) = osteoid surface/ bone surface; and (3) osteoid thickness (O.Th) = (osteoid area/osteoid perimeter) x 2/1.2 . Dynamic histomorphometric parameters were determined from the metaphysis, including (1) percent mineralized bone surface (MS/BS) (%) = ([perimeter of a single labeled surface × 0.5] + [perimeter of a double labeled surface])/(perimeter of the total bone surface); and (2) mineral apposition rate (MAR) (μm/d) = (distance between the 2 fluorescent labels)/(time between the 2 injections of the fluorescent label) x 1.2 . Bone turnover was determined using bone formation rate (BFR) (μm/d) = percent mineralized bone surface × mineral apposition rate. Assessment of mineralization was evaluated by osteoid maturation time (OMT) = O.Th/MAR.
Data analysis was performed with statistical software (SPSS, version 17.0, IBM Corporation, Armonk, NY). Data on figure were presented with mean ± SEM. The others were reported as mean ± SD for continuous variables. Variables those without normal distribution were analyzed after logarithmic transformation for normal distribution. ANOVA and post hoc Games-Howell test were used to compare difference between groups. The relations between serum biomarkers were evaluated using Pearson’s correlation. Univariate regression analysis was performed to assess linear relationships between serum biomarkers and bone parameters. Stepwise multivariate regression analysis was performed to determine the variables had independent association with bone histomorphometric parameters. The probability of entry was 0.05 and removal was 0.1 in stepwise analysis. Two sided p value < 0.05 was considered statistically significant.
Assessment of serum biochemical parameters
The severity of renal failure was similar between the PTX+CKD and the CKD groups (BUN: 61 ± 26 and 68 ± 26 mg/dL, respectively; Cr: 1.2 ± 0.4 and 1.2 ± 0.4 mg/dL, respectively). The mean BUN and Cr levels of the sham-operated control group (BUN: 18 ± 3 mg/dL; Cr: 0.5 ± 0.1 mg/dL) were significant difference from PTX+CKD and CKD groups. (all p < 0.001). The mean serum phosphate levels were significantly higher, and calcium levels were significantly lower in the PTX+CKD animals compared to either the CKD or control groups (Fig 1). The mean serum phosphate and calcium levels were similar between the CKD and sham-operated groups (Fig 1).
(A) Serum phosphate levels. (B) Serum calcium levels. (C) Serum intact PTH levels. (D) Serum FGF-23 levels. (E) Serum Vitamin D (1,25-(OH)2D3) levels. (F) Serum ALP levels. (G) Serum osteocalcin levels. (H) Serum CTX levels. n = 8 control, n = 9 CKD, n = 9 PTX +CKD. Results were presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
Fractional Excretion of Electrolytes
The mean fractional excretion of phosphate was significantly greater in the CKD group than in controls (20 ± 10% and 6 ± 3%, respectively; p = 0.04); there was no significant difference in fractional excretion of phosphate between control and PTX+CKD groups (7 ± 6%) or between the CKD and PTX+CKD groups. Referred to mean fractional excretion of calcium, there was significantly greater (p = 0.01) in the PTX+CKD group (4 ± 3%) than in the control group (0.2 ± 0.1%). But the fraction excretion of calcium in the CKD group (4 ± 4%) was not different to the other two groups.
Circulating Intact PTH Levels
Mean serum intact PTH level was significantly greater in the CKD than in the control group and significantly less in the PTX+CKD compared to the control or CKD group (Fig 1). These PTH levels confirmed the presence of PTX in the PTX+CKD group (lowest PTH levels) and secondary hyperparathyroidism in the CKD group (highest PTH levels).
Assessment of Serum Biomarkers of Bone
Evaluation of bone biomarkers showed that mean ALP was similar for the control, CKD, and PTX+CKD groups (Fig 1). The mean serum osteocalcin level was greater in the CKD and PTX+CKD groups than in the control group. The mean serum FGF-23 levels were significantly different between the 3 groups, being greatest in the CKD group and lowest in the PTX+CKD group. The mean 1,25-(OH)2D3 levels in the CKD group was significantly lower than in the control group, while mean serum levels of CTX, a bone resorption marker , were significantly higher in the CKD group than in the control and PTX+CKD groups. The bone resorption activity was highest in CKD group according to the serum CTX data.
Histomorphometric Bone Parameters
Evaluation of static histomorphometric parameters showed that the mean bone volume ratio and mean trabecular number were significantly greater in the PTX+CKD group than in the control or CKD groups. Mean trabecular thickness was significantly greater, and mean trabecular separation was significantly lower in the PTX+CKD compared to the CKD group (Table 1). Osteoid thickness in the CKD group was significantly greater than in the PTX+CKD group (Table 1), but no other osteoid parameter was significantly different between the groups.
Evaluation of dynamic histomorphometry (Table 1 and Fig 2) showed that the mean percent mineralized bone surface was significantly lower in the PTX+CKD than the CKD group. Mean MAR and mean BFR were significantly different among the three groups, both were highest in the CKD and lowest in the PTX+CKD groups. Following parallel evaluation of serum bone resorption marker levels and bone formation rates, the PTX+CKD group was denominated as having low bone turnover, while the CKD group had high bone turnover. OMT used as a parameter to measure mineralization rates, was not different in among the groups.
The distance between the 2 lines of calcein label is greater in the chronic kidney disease (CKD) than in the control group. The PTX and chronic kidney disease (PTX+CKD) group had fewer areas with 2 labels, and the distance between the 2 lines of calcein label was smaller, indicating lower bone turnover in the PTX+CKD than in the CKD group. Scale bar = 50 μm.
Correlation Study and Regression Analyses
The Pearson’s correlations between various serum biomarkers were analyzed (Table 2). Serum FGF-23 levels correlated with serum intact PTH, CTX, calcium, and phosphate levels. Serum 1,25-(OH)2D3 values correlated with serum intact PTH, osteocalcin, and CTX levels. There was also an association between serum values of intact PTH and CTX. Serum calcium levels also correlated positively with serum intact PTH levels and negatively with serum phosphate levels. In addition, serum phosphate values also correlated with serum intact PTH and osteocalcin values.
Univariate linear regression was used to analyze between serum biomarkers and bone histomorphometric parameters (Table 3). Bone formation rate and MS/BS were associated with serum values of intact PTH, FGF-23, CTX, calcium, and phosphate levels. MAR was associated with circulating concentrations of intact PTH, FGF-23, 1,25-(OH)2D3, CTX, calcium and phosphate. Bone volume ratio correlated with circulating concentrations of intact PTH, FGF-23, CTX, calcium, and phosphate. Bone trabecular thickness was associated with serum FGF-23 and CTX levels. The osteoid parameters OV/BV, OS/BS and O.Th correlated with serum levels of intact PTH, FGF-23, and CTX. In addition, O.Th also correlated with serum calcium levels. The linear regression analysis in this study did not demonstrate any association between biochemical parameters and OMT, used to assess bone mineralization rates.
Bone histomorphometric parameters values as dependent variables.
Stepwise multiple linear regression analyses were performed to investigate any potential independent relationships between biomarkers and bone histomorphometric parameters. Serum biomarkers including intact PTH, FGF-23, ALP, osteocalcin, 1,25-(OH)2D3, CTX, calcium, and phosphate were used as independent variables. Bone histomorphometric parameters were considered dependent variables (Table 4). Serum intact PTH was an independent predictor of bone formation rate and MS/BS. Circulating calcium and 1,25-(OH)2D3 values correlated with MAR. Levels of FGF-23 were independently associated with bone volume parameters: bone volume and bone trabecular thickness. CTX was associated with osteoid parameters. No biochemical parameters could predict OMT in the present study (Table 4).
In the present study, the PTX+CKD and the CKD groups had similar CKD severity; the PTX+CKD group had hypoparathyroidism and the CKD group had secondary hyperparathyroidism (Fig 1). The PTX+CKD group had a low bone formation rate, low serum bone resorption marker values, and low serum FGF-23 levels; conversely, in the CKD group, there was a higher bone formation rate, higher serum bone resorption marker values, and higher serum FGF-23 levels (Table 1 and Fig 1). Stepwise multivariate regression analysis demonstrated that serum FGF-23 independently correlated with bone structure histomorphometric parameters: bone volume and bone trabecular thickness (Table 4). These data were consistent with the hypothesis that FGF-23 correlated with bone histomorphometry, more specifically with bone volume in CKD. Instead, intact PTH was independently associated with bone formation rate and CTX correlated with osteoid parameters.
The hormone PTH has been reported to stimulate FGF-23 secretion in osteocytes [29–31] and to regulate FGF-23 levels in vivo [32,33]. In CKD, secondary hyperparathyroidism induces high levels of serum FGF-23 , and PTX has shown to decrease elevated FGF-23 levels in advanced secondary hyperparathyroidism [22,34] in PTX + CKD rats (Fig 1). Accordingly, in the present study we show that serum FGF-23 levels correlated with serum PTH levels (Table 2).
Phosphate balance is regulated by both PTH and FGF-23. When the serum phosphate level is elevated, PTH and FGF-23 increase the fractional excretion of phosphate by acting on the proximal renal tubules. In CKD, the decline in renal function leads to phosphate retention. FGF-23 serum levels increase and may correlate with total phosphate load in CKD. However, in the PTX+CKD rats in our study, a low mean serum FGF-23 level was noted despite hyperphosphatemia, which was likely related to low mean circulating PTH levels (Fig 1). Thus, in this PTX+CKD group with hypoparathyroidism and low FGF-23 levels, phosphaturia had not increased , although the CKD group had increased fractional excretion of phosphate (as expected in CKD) . Therefore, from our data it appeared that both low PTH and FGF-23 levels had limited phosphate excretion in the PTX+CKD rat model. Other animal studies with hypoparathyroidism or calcium deficiency [20,32] also demonstrated that serum phosphate values are inversely correlated with serum FGF-23 values.
FGF-23 interacts with vitamin-D and serum calcium. FGF-23 inhibits renal production of the active form of vitamin-D , which increases calcium absorption in the intestine. In addition to diminished renal functional mass, the decrease circulating vitamin-D concentrations in CKD patients is caused by the increase in FGF-23 levels and activity . Calcium positively correlates with FGF-23 under hypocalcemia [20, 37]. In a study in which rats fed a low-calcium and low-vitamin D diet, severe hypocalcemia resulted in the decline of FGF-23 levels although serum PTH values were elevated . Hypocalcemia induced by PTX might also contribute to the low circulating FGF-23 levels observed in our PTX+CKD rats. Under severe hypocalcemia, the drop in circulating FGF-23 may raise active form of vitamin D levels and rescue serum calcium levels. In our PTX + CKD rat model, serum calcium levels were all initially less than 6 mg/dL after PTX; however, at the time of euthanization, the mean serum calcium levels rose to 7 mg/dL. Accompanied by low FGF-23 levels in PTX+ CKD animals, 1,25-(OH)2D3 tended to increase exponentially compared to CKD rats. The phenomenon might be related to physiological adaption to severe hypocalcemia and prevention of further adverse effects to other tissues .
Osteodystrophy is a feature of CKD. In the present study, the CKD rats had a high bone turnover associated with secondary hyperparathyroidism (Table 1 and Fig 1) [38, 39]. The PTX+CKD group had a lower bone formation rate because PTX resulted in lower levels of PTH, a hormone necessary for bone cell differentiation. The PTX+CKD group had a concurrent reduction in bone resorption marker levels compared to the CKD group. With regards to the reduced bone formation rate and bone resorption rate , the PTX+CKD group was considered as having low bone turnover in this experimental model . PTH modulates bone cells including the activity of osteocytes, osteoblasts, and osteoclasts. The net influence of PTH on bone metabolism depends on which effect predominates [40,41].
While FGF-23 is mainly produced by osteocytes, it may be associated with bone formation. In our study, FGF-23 levels showed a positive linear association with bone formation rate (Table 3), but in multiple regression analysis, FGF-23 was not an independent predictor of bone formation. Instead, the bone formation rate could be determined by PTH (Table 4). The relationship between bone formation rate and FGF-23 might be secondary to the PTH effect (Table 2). Serum levels of bone non-collagen synthetic markers, serum ALP and osteocalcin are generally used to evaluate bone turnover in CKD . However, after PTX in patients with CKD, bone synthesis markers may increase for a period instead of declining [43–46] and lower bone formation rate occurs at this time . The dissociated change between the bone formation rate and bone synthesis markers was also demonstrated in a study comparing bone histomorphometry before and after PTX in patients with secondary hyperparathyroidism . Serum ALP values increased but the bone resorption reaction decreased after surgery. The number of osteocytes decreased and the presence of empty lacunae increased. The presence of two distinct tetracycline labeled areas could not be distinguished . Instead, mineralization occurred in the osteocyte-canalicular system rather than at the mineralization front. This phenomenon may explain why bone formation rates, calculated using fluorescent labels at the mineralization front, could not positively correlate with ALP and osteocalcin after PTX in our PTX+CKD animals (Table 4).
Both intermittent and continuous treatment with PTH have been reported to increase bone formation rates in animals, while bone volume could be increased by intermittent supplement but decreased by continuous supplement . Overall, bone volume is determined by the net effect of bone anabolism and catabolism . Secondary hyperparathyroidism in CKD is similar to that observed with persistent exposure to PTH. High serum levels of resorption marker, CTX, were observed in our CKD rats (Table 1) and they had high catabolism rate and low bone volume parameters. Increased bone mineral density after PTX can be seen both in patients with primary hyperparathyroidism and secondary hyperparathyroidism related to CKD  as bone resorption decreases . Our PTX+CKD rats were observed with highest bone volume parameters. Osteoid thickness decreased after PTX, while osteoid volume and osteoid surface did not differ in our rats. Osteoid parameters correlated with CTX, which presumably indicated that as more collagen cumulates, more degraded products could be generated. Parameters of mineralization assessment such as osteoid maturation time did not differ among the three groups (Table 1).
Osteocytes participate in bone remodeling by interacting with osteoblasts and osteoclasts, or by secreting systemic regulators that control mineral metabolism [7,41]. According to bone-renal axis in normal physiology, FGF-23 induces phosphaturia when the body is exposed to phosphate load. The increase in FGF-23 also inhibits renal synthesis of 1,25-(OH)2D by suppressing vitamin D-activating enzyme 1α-hydroxylase . FGF-23 affects mineral metabolism by coordinating bone mineralization. Increased bone volume may up-regulate FGF-23 to excrete excess phosphate through the kidney and further suppress bone mineralization. Administration of bone formation promoter or anti-resorption agents affected bone metabolism and serum FGF-23 levels in one animal study . The authors showed that supplementation with PTH forced an increase in the bone formation rate. The requirement for minerals increased at this phase and FGF-23 secretion was decreased in order to reduce mineral loss. When osteoprotegerin (OPG) was administered, the resorption of bone declined and bone volume increased as a primary effect. Consequently, the bone formation rate slowed down to prevent further increases in bone volume. The overall mineral requirement decreased and FGF-23 secretion was enhanced.
However, the normal physiology of the bone-renal axis is disrupted in CKD. With renal impairment, the retention of phosphate burden persistently induces PTH and FGF-23 expression. As a result, the physiological interplay regulating FGF-23, PTH, and bone metabolism in CKD may differ from those with normal renal function. In a large prospective case-cohort study, the data showed that higher levels of serum FGF-23 were associated with fracture risk in elderly men with decreased renal function but not in those without renal impairment . How mineral imbalance, hormone dysregulation, or other pathophysiology in CKD affects the interplay between FGF-23 and bone metabolism requires further study. In contrast, FGF-23 was shown to inhibit bone matrix mineralization in in vitro studies [49,50]. A negative association between FGF-23 and bone mineral density or bone volume parameters was shown in patients with CKD , while in some previous studies, this relationship was not observed . The authors concluded that these divergent findings might be related to different measurement sites or to the method selected to detect bone density . In addition, the role played by FGF-23 in phosphate regulation and bone metabolism is likely different in diabetes mellitus patients from those without diabetes mellitus [53–55]. Therefore, the numbers of diabetes mellitus patients included in the above studies could have affected the final results. The relationship between plasma FGF-23 values and bone histomorphometric parameters in pediatric and young adult CKD patients had been previously reported in series studies from the same group [56–58]. In the children who received peritoneal dialysis supplied with oral calcitriol, serum FGF-23 independently correlated with osteoid parameters and osteoid maturation time . However, in young patients with CKD stage 2–5 without dialysis, circulating FGF-23 was not consistent with the above and poorly predicted the bone formation rate. Instead, serum PTH values were independently associated with increased osteoid accumulation and circulating phosphate concentrations independently correlated with osteoid accumulation and osteoid maturation time . The authors concluded that renal FGF-23 excretion might obscure the relationship between FGF-23 and bone histomorphometric variables in predialysis CKD patients. This may explain why no correlation was observed between our FGF-23 values and the osteoid parameters. In addition, the variables included in our stepwise analysis might have influenced the final results. In our study, serum CTX was analyzed and associated with the osteoid parameters after stepwise analysis. Conversely, FGF-23 negatively correlated with bone volume in the above-mentioned pediatric patients on peritoneal dialysis in bivariate analysis , while this relationship was not seen in young CKD patients without dialysis . The bone volumes of these CKD patients were either normal or increased although most had high serum PTH and FGF-23 levels. The bone growth-inducing properties of other endogenous circulating growth hormones in these young patients and may have obscured the association between FGF-23 and bone volume parameters that was observed in our animals.
PTX resulted in an extremely high phosphate burden in the PTX+CKD group. Interestingly, FGF-23 decreased rather than increased in this experimental model. Since serum FGF-23 values were still independently correlated with bone volume, FGF-23 might exert specific actions on bone that are independent of its effects on bone mineralization. This should be confirmed with further experiments. Our study demonstrated the relationship between FGF-23, other biochemical markers, and bone histomorphometric parameters with the intention to provide a better understanding of bone metabolism in CKD. Limitations of the present study include the absence of data regarding potential of cause and effect relationships linking biomarkers and bone parameters. In the future, the experiment that treated with various concentration of FGF-23 in FGF-23 knock-out + CKD animal is a way to evaluate the sole effect of FGF-23 on bone. In addition, our study was based on animal models instead of humans. Further animal or clinical studies should take into consideration other etiologies, such as diabetes mellitus, which lead to low turnover bone in CKD.
In conclusion, the rat model with CKD and secondary hyperparathyroidism (CKD group) had high serum FGF-23 levels and high bone turnover. Although in the presence of hyperphosphatemia, serum FGF-23 levels decreased in the CKD rat model with hypoparathyroidism (PTX+CKD group) and had low bone turnover. According to stepwise multivariate regression analysis, circulating FGF-23 levels independently correlated with bone volume. In addition, in the present study, serum PTH independently correlated with bone formation rate, and CTX was associated with osteoid parameters.
This article is revised by M.D. Yu-Ru Liao, Physician of An-Li Pediatric and Medical Clinic, Pu-Li, Nantou, Taiwan. This study was partly supported by National Cheng Kung University Hospital (NCKUH-10408012) and National Cheng Kung University.
Conceived and designed the experiments: HWL KJT. Performed the experiments: HWL PHH CYH HSL. Analyzed the data: HWL HHL. Contributed reagents/materials/analysis tools: KJT THH IMJ. Wrote the paper: HWL KJT.
- 1. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007;18: 875–885. pmid:17251386
- 2. West SL, Lok CE, Jamal SA. Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World Environments (FRACTURE): a prospective study. BMC Nephrol. 2010;11: 17. pmid:20727179
- 3. Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant. 2011;26: 1010–1015. pmid:20709740
- 4. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44: 672–679. pmid:15384018
- 5. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl. 2009;114: S34–S42. pmid:19946326
- 6. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, et al. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40: 1565–1573. pmid:17350357
- 7. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26: 229–238. pmid:21254230
- 8. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314: 409–414. pmid:14733920
- 9. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis.J Endocrinol. 2007;194: 1–10. pmid:17592015
- 10. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006;70: 2141–2147. pmid:17063170
- 11. Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. 2011;6: 383–389. pmid:21030580
- 12. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75: 1297–1307. pmid:19322138
- 13. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, et al. Fibroblast Growth factor-23 in Early Chronic Kidney Disease: Additional Support in Favor of a Phosphate-Centric Paradigm for the Pathogenesis of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5: 1268–76. pmid:20448073
- 14. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16: 2205–2215. pmid:15917335
- 15. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150: 4835–45. pmid:19819968
- 16. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333: 166–174. pmid:7791820
- 17. Fukagawa M, Kazama JJ, Kurokawa K.Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant. 2003;17 Suppl 10: 2–5
- 18. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res. 2012;27: 38–46. pmid:22031097
- 19. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ,Hampson G. Fibroblast growth factor-23 is associated with C-reaction protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010;21: 1853–61. pmid:20012018
- 20. Rodriguez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, Martinez-Moreno JM, Ramírez AP, Pineda C, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephro. 2012;23: 1190–7.
- 21. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moysés RM, et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uremia. Nephrol Dial Transplant. 2009;24: 1416–1421. pmid:19075196
- 22. Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin? PLos One. 2013;8: e79721. pmid:24236156
- 23. Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int. 1991;40: 1063–1068. pmid:1762307
- 24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2: 595–610. pmid:3455637
- 25. Glurieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, et al. Normative data for iliac bone histomorphometry in growing children. Bone. 2000;26: 103–9. pmid:10678403
- 26. Ott SM. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol. 2008;3 Suppl 3: S151–S156. pmid:18988700
- 27. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69: 1945–1953. pmid:16641930
- 28. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;11: 201. pmid:23984630
- 29. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011;49: 636–643. pmid:21726676
- 30. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.Bone. 2007;40: 1434–1446. pmid:17517365
- 31. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299: F882–F889. pmid:20685823
- 32. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, de Oca AM, Pineda C, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011;80: 475–482. pmid:21525854
- 33. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;8: 2683–2688.
- 34. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44: 481–7. pmid:15332221
- 35. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D 1-alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293: F1577–83. pmid:17699549
- 36. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008;23: 2733–7. pmid:18469306
- 37. David V, Dai B, Martin A, Huang J, Han X. Calcium regulates FGF-23 expression in bone. Endocrinology 2013;154: 4469–82. pmid:24140714
- 38. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int. 1993;43: 436–42. pmid:8441240
- 39. Rauch F. Watching bone cells at works: what can we see from bone biopsies 2006;21: 457–462.
- 40. Li X, Liu H, Qin L, Tamasi J, Bergenstock M, Shapses S, et al. Determination of duel effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007;282: 33086–97. pmid:17690103
- 41. Eriksen EF. Cellular mechanism of bone remodeling. Rev Endocr Metab Disord. 2010;11: 219–27. pmid:21188536
- 42. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007;18: 875–85. pmid:17251386
- 43. Yajima A, Inaba M, Tominaga Y, Nishizawa Y, Ikeda K, Ito A, et al. Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism. J Bone Miner Res. 2010;25: 2374–81. pmid:20499355
- 44. Peretz AM, Dhaene MM, Drowart A, Kinnaert P, Vertongen FM, Bourdoux PP, et al. Evolution of osteocalcin, alkaline phosphatase and parathyroid hormone after parathyroidectomy in patients receiving chronic maintenance hemodialysis. J Rheumatol. 1992;19: 411–415. pmid:1578455
- 45. Mazzaferro S, Chicca S, Pasquali M, Zaraca F, Ballanti P, Taggi F, et al. Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration. Nephrol Dial Transplant. 2000;15: 877–82. pmid:10831645
- 46. Lu KC, Ma WY, Yu JC, Wu CC, Chu P. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism. Clin Endocrinol. 2012;76: 634–42.
- 47. Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998;83: 3845–51. pmid:9814456
- 48. Lane NE, Parimi N, Corr M, Yao W, Cauley JA, Nielson CM,et al. Association of Serum Fibroblast Growth Factor 23 (FGF23) and Incident Fractures in Older Men: The Osteoporotic Fractures in Men (MROS) Study. J Bone Miner Res. 2013;28: 2325–32. pmid:23677793
- 49. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N,et al. Fibroblast growth factor (FGF-23) and alpha-kltho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int. 2011;89: 140–50. pmid:21633782
- 50. Mackenzie NC, Zhu D, Milne EM, van 't Hof R, Martin A, Darryl Quarles L, et al. Altered bone development and an increase in FGF-23 expression in Enpp(-/-) mice. PLos one 2012;7: e32177. pmid:22359666
- 51. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G, et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010;21: 1853–1861. pmid:20012018
- 52. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patient at various CKD stages. Osteoporos Int. 2012;23: 2017–25. pmid:22109743
- 53. Muras K, Masajtis-Zagajewska A, Nowicki M. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease. J Clin Endocrinol Metab. 2013;98: E1901–E1908. pmid:24092829
- 54. Yoda K, Imanishi Y, Yoda M, Mishima T, Ichii M, Yamada S, et al. Impair response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab. 2012;97: E2036–43. pmid:22893717
- 55. Reyes-Garcia R, Garcia-Martín A, García-Fontana B, Morales-Santana S, Rozas-Moreno P, Muñoz-Torres M. FGF23 in type 2 diabetic patients: relationship between bone metabolism and vascular disease. Diabetes Care 2014;37: e89–90. pmid:24757249
- 56. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone. 2009;45: 1161–1168. pmid:19679205
- 57. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009;94: 511–7. pmid:19050056
- 58. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7: 146–52. pmid:22052943